Literature DB >> 21609290

Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: a pilot study.

Takumi Kawaguchi1, Naoto Shiba, Yoshio Takano, Takashi Maeda, Michio Sata.   

Abstract

A new muscle-training method, "hybrid training", utilizing combined voluntary and electrical muscle contractions, is effective for increasing muscle mass and force on lower extremities in elderly people. Although skeletal muscle regulates glucose metabolism, partly by releasing interleukin (IL)-6, the effects of hybrid training on glucose metabolism remains unclear. The aim of this study was to investigate the effects of hybrid training on glucose metabolism and serum IL-6 levels in elderly people. Hybrid training was performed on 7 elderly subjects. Both quadriceps and hamstrings were contracted voluntarily or electrically at the same time for 19 min twice a week. The effects on glucose metabolism and serum IL-6 levels were evaluated after 12 weeks of hybrid training. All of the subjects completed the study, and no severe adverse events developed during the study period. There were no significant differences in body mass index, serum insulin levels, homeostasis model assessment for insulin resistance values, or hemoglobin A1c values after hybrid training. However, fasting blood glucose levels were significantly decreased after hybrid training (114 ± 13 vs. 103 ± 9 mg·dL(-1); p = 0.0340). In addition, all 7 subjects showed a decrease in serum IL-6 levels after hybrid training, and this decrease was statistically significant (44.0 ± 35.6 vs. 14.6 ± 10.5 pg·mL(-1); p = 0.0180). Furthermore, there was a significant correlation between changes in serum IL-6 levels and changes in fasting blood glucose levels (ρ = 0.883; p = 0.0306). In this study, we showed the safety and good adherence of hybrid training for lower extremities in elderly people. Furthermore, hybrid training decreased fasting blood glucose and serum IL-6 levels in elderly people.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609290     DOI: 10.1139/h10-108

Source DB:  PubMed          Journal:  Appl Physiol Nutr Metab        ISSN: 1715-5312            Impact factor:   2.665


  5 in total

Review 1.  Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

2.  Electrically Stimulated Antagonist Muscle Contraction Increased Muscle Mass and Bone Mineral Density of One Astronaut - Initial Verification on the International Space Station.

Authors:  Naoto Shiba; Hiroo Matsuse; Yoshio Takano; Kazuhiro Yoshimitsu; Masayuki Omoto; Ryuki Hashida; Yoshihiko Tagawa; Tomohisa Inada; Shin Yamada; Hiroshi Ohshima
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 3.  Targeting Inflammation by Flavonoids: Novel Therapeutic Strategy for Metabolic Disorders.

Authors:  Mohammad Hosein Farzaei; Amit Kumar Singh; Ramesh Kumar; Courtney R Croley; Abhay K Pandey; Ericsson Coy-Barrera; Jayanta Kumar Patra; Gitishree Das; Rout George Kerry; Giuseppe Annunziata; Gian Carlo Tenore; Haroon Khan; Matteo Micucci; Roberta Budriesi; Saeideh Momtaz; Seyed Mohammad Nabavi; Anupam Bishayee
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

4.  Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Tetsuharu Oriishi; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2012-08-09

5.  Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: a pilot trial.

Authors:  Sechang Oh; Tsuyoshi Maruyama; Kiyoshi Eguchi; Takashi Shida; Emi Arai; Tomonori Isobe; Yoshikazu Okamoto; Junichi Shoda
Journal:  Ther Clin Risk Manag       Date:  2015-03-04       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.